ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer

Table 3

Relationship between all variables and survival rate.

Characteristics	Status				HR (IK 95%)
	Died		Live
	n	%	n	%
Ages
≥50 years	10	40.00	15	60.00	Reff
<50 years	14	48.28	15	51.72	1.294 (0.574–2.916)	0.535
Tumor size
T1-T2	3	20.00	12	80.00	Reff
T3	2	14.29	12	85.71	0.859 (0.142–5.143)	0.868
T4	19	76.00	6	24.00	6.935 (2.019–23.819)	0.002
Lymph node metastasis
N0-N1	19	42.22	26	57.78	Reff
N2	2	50.00	2	50.00	0.966 (0.223–4.175)	0.963
N3	3	60.00	2	40.00	2.020 (0.595–6.858)	0.260
Distant metastasis
Negative	9	23.08	30	76.92	Reff
Positive	15	100.00	0	0.00	14.894 (5.909–37.54)	<0.001
Histological grading
1	1	50.00	1	50.00	Reff
2	12	42.86	16	57.14	0.603 (0.078–4.669)	0,628
3	11	45.83	13	54.17	0.631 (0,081–4,936)	0.661
Ki67
<20%	4	40.00	6	60.00	Reff
≥20%	20	46.51	23	53.49	1.238 (0.422–3.630)	0.697
Stadium
Early	2	10.00	18	90.00	Reff
Advance local	7	36.84	12	63.16	4.544 (0.942–21.921)	0.059
Advance	15	100.00	0	0.00	38.309 (8.247–177.950)	<0.001
Chemotherapy
TC	12	44.44	15	55.56	Reff
CAF/CEF	8	38.10	13	61.90	1.741 (0.698–4.342)	0.235
Others	4	80.00	1	20.00	3.422 (1.103–10.610)	0.033
Recurrence
Negative	21	45.65	25	54.35	Reff
Positive	3	37.50	5	62.50	1.493(0.444–5.024)	0.517
Radiotherapy
Negative	9	40.91	13	59.09	Reff
Positive	15	48.39	16	51.61	0.811 (0.354–1.856)	0.620